SCHEMBL2118381

SCHEMBL2118381

Cc1ccc(-c2cccs2)cc1N(C)S(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.43
HSD17B2 P37059 3/20 0.43
CYP2C9 P11712 2/20 0.43
C5AR1 P21730 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
MMP2 P08253 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ERN1 O75460 1/20 0.39
KAT6A Q92794 1/20 0.38
GHSR Q92847 1/20 0.38
LMNA P02545 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
SCD O00767 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2122135 0.88 LMNA (0.41) CYP2C9C5AR1CA12CA1CA2
SCHEMBL2120607 0.88 PSEN1 (0.45) CYP2C9C5AR1CA12CA1CA2
SCHEMBL2118160 0.81 CYP2E1 (0.45) CYP2C9RAB9AKAT6AGHSRLMNA
SCHEMBL2119838 0.80 HSD17B1 (0.44) HSD17B1HSD17B2CYP2C9C5AR1NPC1
SCHEMBL2117311 0.76 HSD17B1 (0.43) HSD17B1HSD17B2CYP2C9C5AR1NPC1
SCHEMBL2119380 0.76 LMNA (0.39) CYP2C9NPC1RAB9ALMNAHDAC3
SCHEMBL2119048 0.75 GHSR (0.58) HSD17B1HSD17B2CYP2C9CA12CA1
SCHEMBL2117632 0.75 HSD17B1 (0.44) HSD17B1HSD17B2CYP2C9C5AR1NPC1
SCHEMBL7053207 0.74 KDM4E (0.50) CA12CA1CA2MMP2CA9
SCHEMBL1062982 0.71 LTA4H (0.57) CYP2C9NPC1ERN1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 HSD17B1 3178/4885HSD17B2 3651/4885CYP2C9 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.